SRPT
Sarepta Therapeutics,, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Sarepta Therapeutics (SRPT) Stock: Buy, Sell, or Hold?
$16.42
-0.82 (-4.76%)
▼
5d:
-11.43%
30d:
-5.85%
90d:
-10.66%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 05, 2026
0d
Protect SRPT Gains
Updated Nov 10, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
33/100
Position
OVERSOLD
30-Day Fair Range
$17.15 – $18.70
Position: OVERSOLD
Forward P/E & Valuation
7.5x
FAIR
vs 6.9x historical avg
Wall Street Target
$21.59
+31.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$16.14 / $19.68
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: SRPT is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 9, 2026 at $17.24 · last confirmed Nov 9, 2026
Strength: 6.0/10
Get Alerted When SRPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.80
Based on -21.9% avg growth
INTRINSIC VALUE TODAY
$2.36
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SRPT is currently trading at $16.42, which is considered oversold relative to its 30-day fair value range of $17.15 to $18.70. The stock's valuation (Forward PE: 7.5) is in line with its historical norms (6.9). At these levels, the market is pricing in 2.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $16.14. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: SRPT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.59 (+31.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SRPT is in a strong downtrend. The price is currently testing key support at $16.14. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: SRPT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.59 (+31.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$17.15 -
$18.70
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
53.3%
Trading Range & Key Levels
30-Day Trading Range
$17.15 -
$18.70
Current vs Trading Range
OVERSOLD
Support Level
$16.14
Resistance Level
$19.68
Current Trend
Strong Downtrend
Technical data as of
Nov 10, 2026
Protect Your Profits
Holding SRPT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 31.5% below Wall St target ($21.59)
- NEUTRAL: Market pricing in 2.7% annual earnings growth - fairly valued
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
7.49
Wall Street Target
$21.59
(+31.5%)
Revenue Growth (YoY)
-4.5%
Earnings Growth (YoY)
2663.8%
Profit Margin
-5.9%
Valuation Premium vs History
+2.7% premium
PE vs Historical
7.5 vs 6.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.7%
(market-implied from PE analysis)
1-Year Target
$16.86
(+3%)
2-Year Target
$17.32
(+6%)
3-Year Target
$17.79
(+8%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$16.38
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: -47.8%)
$31.72
(+93%)
Base:
(SPY PE: 7.5, Growth: -47.8%)
$11.97
(-27%)
Bear:
(PE: 6.4, Growth: -47.8%)
$10.17
(-38%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Forward PE: 18.02 | Forward EPS (Implied): $0.91
Bull Case
$19.83
(+21%)
Analyst growth 15.0%, PE expands to 18.9
Base Case
$16.42
(0%)
Market implied 0.0%, PE stable at 18.0
Bear Case
$12.56
(-24%)
Severe decline -15.0%, PE contracts to 16.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share SRPT Analysis
Share this live SRPT analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (SRPT)
Bearish
4 Retail Mentions
Reddit / WSB Comments
2
Bearish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
CEO Michael Severino of Sarepta Therapeutics ($SRPT) expressed optimism about the company's future, expecting updates from its rare disease programs to drive growth in 2027. The Duchenne muscular dystrophy business is expected to fund development.
Key Retail Themes:
Company expectations for transformational growth in 2027
Advancement of rare disease programs
Reliance on Duchenne business for funding development
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:53 AM ET
Data refreshes hourly during market hours. Next update: 9:52 AM
Data refreshes hourly during market hours. Next update: 9:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 62 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 41 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 55 HOLD |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 60 BUY |
|
RZLT
Rezolute Inc |
STRONG BUY
11 analysts |
$10 | 72 BUY |
Advanced SRPT Option Strategies
Professional options setups generated by AI based on today's SRPT price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive SRPT Research Pages
